Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7695-7703

  Pannellini, Tania ^a   Spadaro, Michela ^b   Di Carlo, Emma ^a   Ambrosino, Elena ^b   Iezzi, Manuela ^a   Amici, Augusto ^c   Lollini, Pier Luigi ^d   Forni, Guido ^b   Cavallo, Federica ^b   Musiani, Piero ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL MEDIATED CYTOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; ELECTROPORATION; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSFORMATION; MALE; MOUSE; NONHUMAN; ONCOGENE; PAROTID GLAND CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 33744941076     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7695     Document Type: Article

References (60)

1. Speight, P. M., and A. W. Barrett. 2002. Salivary gland tumours. Oral Dis. 8: 229-240.
2. Sessions, R. B., L. B. Harrison, and A. A. Forastiere. 2001. Tumors of the salivary glands and paraganglioma. In Cancer: Principles and Practice of Oncology. V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg, eds. Lippincott Williams & Wilkins, Philadelphia, pp. 886-906.
3. Gooden, E., I. J. Witterick, D. Hacker, I. B. Rosen, and J. L. Freeman. 2002, Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital's quality assurance review. J. Otolaryngol 31: 351-354.
4. Skalova, A., Starek, V. Kucerova, P. Szepe, and L. Plank. 2001. Salivary duct carcinoma - a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol. Res. Pract. 197: 621-626.
5. Nguyen, L. H., M. J. Black, M. Hier, P. Chauvin, and L. Rochon. 2003. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J. Otolaryngol. 32: 328-331.
6. Skalova, A., I. Starek, T. Vanecek, V. Kucerova, L. Plank, P. Szepe, S. Di Palma, and I. Leivo. 2003. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42: 348-356.
7. Etges, A., D. S. Pinto, Jr., L. P. Kowalski, F. A. Soares, and V. C. Araujo. 2003. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J. Clin. Pathol. 56: 914-918.
8. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
9. Kokai, Y., J. N. Myers, T. Wada, V. I. Brown, C. M. LeVea, J. G. Davis, K. Dobashi, and M. I. Greene. 1989. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287-292.
10. Di Fiore, P. P., O. Segatto, W. G. Taylor, S. A. Aaronson, and J. H. Pierce. 1990. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 248: 79-83.
11. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2: 127-137.
12. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188: 589-596.
13. Diodoro, M. G., E. Di Carlo, R. Zappacosta, M. Iezzi, A. Coletti, A. Modesti, T. D'Antuono, G. Forni, and P. Musiani. 2000. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. Int. J. Cancer 88: 329-335.
14. Nordkvist, A., E. Roijer, G. Bang, H. Gustafsson, M. Behrendt, W. Ryd, S. Thoresen, K. Donath, and G. Stenman. 2000. Expression and mutation patterns of p53 in benign and malignant salivary gland tumors. Int. J. Oncol. 16: 477-483.
15. Ohki, K., H. Kumamoto, R. Ichinohasama, M. Suzuki, T. Yamaguchi, S. Echigo, K. Motegi, and K. Ooya. 2001. Genetic analysis of DNA microsatellite loci in salivary gland tumours: comparison with immunohistochemical detection of hMSH2 and p53 proteins. Int. J. Oral Maxillofac. Surg. 30: 538-544.
16. Ohtake, S., J. Cheng, H. Ida, M. Suzuki, K. Ohshiro, W. Zhang, and T. Saku. 2002. Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J. Oral Pathol. Med. 31: 590-597.
17. Horak, E., K. Smith, L. Bromley, S. LeJeune, M. Greenall, D. Lane, and A. L. Harris. 1991. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-2284.
18. Croci, S.. G. Nicoletti, L. Landuzzi, C. De Giovanni, A. Astolfi, C. Marini, E. Di Carlo, P. Musiani, G. Forni, P. Nanni, and P. L. Lollini. 2004. Immunological prevention of a multigene cancer syndrome. Cancer Res. 64: 8428-8434.
19. Akashi, M., and H. P. Koeffler. 1998. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin. Obstet. Gynecol. 41: 172-199.
20. Attardi, L. D., and T. Jacks. 1999. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol. Life Sci. 55: 48-63.
21. Li, B., K. L. Murphy, R. Laucirica, F. Kittrell, D. Medina, and J. M. Rosen. 1998. A transgenic mouse model for mammary carcinogenesis. Oncogene 16: 997-1007.
22. Olive, K. P., D. A. Tuveson, Z. C. Ruhe, B. Yin, N. A. Willis, R. T. Bronson, D. Crowley, and T. Jacks. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
23. Lang, G. A., T. Iwakuma, Y. A. Suh, G. Liu, V. A. Rao, J. M. Parant, Y. A. Valentin-Vega, T. Terzian, L. C. Caldwell, L. C. Strong, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
24. Spadaro, M., E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W. Z. Wei, P. Musiani, P. L. Lollini, et al. 2005. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11: 1941-1952.
25. Boggio, K., E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, and G. Forni. 2000. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res. 60: 359-364.
26. Rovero, S., A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165: 5133-5142.
27. Di Carlo, E., S. Rovero, K. Boggio, E. Quaglino, A. Amici, A. Smorlesi, G. Forni, and P. Musiani. 2001. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin. Cancer Res. 7: 830s-837s.
28. Quaglino, E., S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P. L. Lollini, S. Lanzardo, G. Forni, R. Sanges, et al. 2004. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113: 709-717.
29. Quaglino, E., M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al. 2004. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res. 64: 2858-2864.
30. Ritchie, D. S., I. F. Hermans, J. M. Lumsden, C. B. Scanga, J. M. Roberts, J. Yang, R. A. Kemp, and F. Ronchese. 2000. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J. Immunol. Methods 246: 109-117.
31. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, K. Furukawa, T. Kanematsu, and H. Shiku: 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159: 1336-1343.
32. Pannellini, T., G. Forni, and P. Musiani. 2004. Immunobiology of HER-2/neu transgenic mice. Breast Dis. 20: 33-42.
33. Tsunoda, T., H. Inada, I. Kalembeyi, K. Imanaka-Yoshida, M. Sakakibara, R. Okada, K. Katsuta, T. Sakakura, Y. Majima, and T. Yoshida. 2003. Involvement of large tenascin-C splice variants in breast cancer progression. Am. J. Pathol. 162: 1857-1867.
34. Jahkola, T., T. Toivonen, I. Virtanen, K. von Smitten, S. Nordling, K. von Boguslawski, C. Haglund, H. Nevanlinna, and C. Blomqvist. 1998. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br. J. Cancer 78: 1507-1513.
35. Cifaldi, L., E. Quaglino, E. Di Carlo, P. Musiani, M. Spadaro, P. L. Lollini, S. Wolf, K. Boggio, G. Forni, and F. Cavallo. 2001. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res. 61: 2809-2812.
36. Podsypanina, K., Y. Li, and H. E. Varmus. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med. 2: 24.
37. Liu, S., W. Liu, J. L. Jakubczak, G. L. Erexson, K. R. Tindall, R. Chan, W. J. Muller, S. Adhya, S. Garges, and G. Merlino. 2002. Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 99: 3770-3775.
38. Huang, G. C., S. Hobbs, M. Walton, and R. J. Epstein. 2002. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br. J. Cancer 86: 1104-1109.
39. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
40. Pinkstaff, C. A. 1998. Salivary gland sexual dimorphism: a brief review. Eur. J. Morphol. 36 Suppl: 31-34.
41. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569-3576.
42. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
43. Ria, F., P. van den Elzen, L. T. Madakamutil, J. E. Miller, E. Maverakis, and E. E. Sercarz. 2001. Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. Curr. Mol. Med. 1: 297-304.
44. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174: 4228-4236.
45. Sakai, Y., B. J. Morrison, J. D. Burke, J. M. Park, M. Terabe, J. E. Janik, G. Forni, J. A. Berzofsky, and J. C. Morris. 2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64: 8022-8028.
46. Nanni, P., L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, P. Musiani, et al. 2004. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J. Immunol. 173: 2288-2296.
47. Klapper, L. N., N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden, and M. Sela. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14: 2099-2109.
48. Katsumata, M., T. Okudaira, A. Samanta, D. P. Clark, J. A. Drebin, P. Jolicoeur, and M. I. Greene. 1995. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med. 1: 644-648.
49. Yip, Y. L., and R. L. Ward. 2002. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol. Immunother. 50: 569-587.
50. Klapper, L. N., H. Waterman, M. Sela, and Y. Yarden. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60: 3384-3388.
51. Sliwkowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26: 60-70.
52. Chattergoon, M. A., V. Saulino, J. P. Shames, J. Stein, L. J. Montaner, and D. B. Weiner. 2004. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 22: 1744-1750.
53. Cui, F. D., H. Asada, M. L. Jin, T. Kishida, M. Shin-Ya, T. Nakaya, M. Kita, M. Ishii, M. Iwai, T. Okanoue, et al. 2005. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther. 12: 160-168.
54. + CTL responses. Vaccine 23: 236-246.
55. Cavallo, F., E. Quaglino, L. Cifaldi, E. Di Carlo, A. Andre, P. Bernabei, P. Musiani, G. Forni, and R. A. Calogero. 2001. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res. 61: 3518-3523.
56. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91: 3916-3920.
57. Forni, G., P. L. Lollini, P. Musiani, and M. P. Colombo. 2000. Immunoprevention of cancer: is the time ripe? Cancer Res. 60: 2571-2575.
58. Finn, O. J. 2003. Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198: 1623-1626.
59. Vogelstein, B., and K. W. Kinzler. 2004. Cancer genes and the pathways they control. Nat. Med. 10: 789-799.
60. Lollini, P. L., F. Cavallo, P. Nanni, and G. Forni. 2006. Vaccines for tumour prevention. Nat. Rev. Cancer. 6: 204-216.